SALT LAKE CITY , Aug. 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company ® (NASDAQ: SERA ), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its management team will participate in the following upcoming investor conference: UBS Genomic Medicine Summit, August 13-14 .
President and Chief Executive Officer, Zhenya Lindgardt , will participate in a panel discussion: Future of Genetic Testing – Babies and Beyond , on August 14 at 8:00 a.m. Pacific Time / 11:00 a.
m. Eastern Time . Live audio of the webcast will be available online from the Investors page of the Company's website at www.
seraprognostics.com . The webcast will be archived on the Investors page and will be available for 90 days.
About Sera Prognostics, Inc. Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery.
Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM ® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in .